[January 13, 2011 Staff Accountant Division ofrporation Finance 100 F Street, N.E. Re: Biostar Pharmaceuticals, Form 10-K for the Year Ended December 31, 2009 Filed March 31, 2010 File No. 001-34708 Dear Keira Nakada: The purpose of this letter is to provide thempanys responses to the December 29, 2010mment letter (themment Letter) to Mr. Ronghua]
[Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range BEIJING, Jan. 6, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today its preliminary unaudited sales range for the fourth quarter and full year ended December 31, 2010. A conference call to discuss these preliminary sales will be held on January 6,] [FORM 6-K THE __________ __________ SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F o o SINOVAC BIOTECH LTD.]
[Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range BEIJING, Jan. 6, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today its preliminary unaudited sales range for the fourth quarter and full year ended December 31, 2010. A conference call to discuss these preliminary sales will be held on January 6,] [FORM 6-K THE __________ __________ SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F o o SINOVAC BIOTECH LTD.]
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4]
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4]
[Item 5.07. ach of the seven (7) director-nominees: Name of Nominee Votes For]
[Item 5.07. ach of the seven (7) director-nominees: Name of Nominee Votes For]
[Item 5.07. ach of the seven (7) director-nominees: Name of Nominee Votes For Votes Withheld Weibing Lu 3,175,125 9,912 Wei Wen 3,175,125 9,912 Mark D. Chen 3,043,441 141,596 R.ott Cramer 3,175,125 9,912 Qiang Fan 3,177,079 7,958 Chengtun Qu 3,182,079 2,958 Shouguo Zhao 3,177,079 7,958ystar Bio-Pharmaceuticalmpany Weibing Lu Chief Executive Officer]
[Item 5.07. ach of the seven (7) director-nominees: Name of Nominee Votes For Votes Withheld Weibing Lu 3,175,125 9,912 Wei Wen 3,175,125 9,912 Mark D. Chen 3,043,441 141,596 R.ott Cramer 3,175,125 9,912 Qiang Fan 3,177,079 7,958 Chengtun Qu 3,182,079 2,958 Shouguo Zhao 3,177,079 7,958ystar Bio-Pharmaceuticalmpany Weibing Lu Chief Executive Officer]
[Sinovac Receives SFDA Approval to Commence Clinical Trials For Inactivated Enterovirus Type 71 Vaccine BEIJING, December 28, 2010 /PRNewswire-Asia/ Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it received approval from the China State Food and Drug Administration (SFDA) to commence clinical trials for its proprietary inactivated EV71 vaccine against Hand,] [BEIJING, December 31, 2010 /PRNewswire-Asia/ Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its common shares will be listed on the NASDAQ Global Select Market effective January 3, 2011. The Company received notification from the NASDAQ Stock Market dated December 7, 2010 that as part of the exchanges annual review of Global] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]
